In this episode of Caring for Both, a Curbside Consult Series by the American Association of Pro-Life Obstetricians and Gynecologists (AAPLOG), Jordan Butler sits down with Dr. Christina Francis, CEO of AAPLOG, to discuss a critical letter recently sent to the FDA and HHS. The letter urges immediate review of mifepristone—the first drug in the two-pill regimen commonly used for chemical abortions—amid growing concerns about safety and oversight.

Dr. Francis explains why AAPLOG is sounding the alarm now, what the data really show about complication rates, and how the dismantling of safeguards like in-person evaluations and ultrasounds has impacted women’s health. We’ll also explore the real-world consequences of these policy changes and what steps can be taken to restore transparency and protect patients.

If you find this episode helpful, please subscribe, leave a review, and share it with colleagues who care about evidence-based, life-affirming medicine.

Resources Mentioned:

• Fact Sheet: Deficiencies Affecting U.S. Abortion Data Collection and Application - Lozier Institute
• Hear from Rosalie on Her Chemical Abortion Pill Experience
• AAPLOG Conference - MBEC 2026

Learn more about us at www.aaplog.org

Become a member at www.aaplog.org/join

Join our mailing list here.

Click here to donate.

Follow us on:
Facebook
Twitter
Instagram